 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
9 News |  |
- | Review, Journal: Cardiac Na/Ca exchange stimulators among cardioprotective drugs. (Pubmed Central) - May 13, 2020
Cardiac Na/Ca exchange current (I) was stimulated by nicorandil (a hybrid ATP-sensitive K channel opener), pinacidil (a non-selective ATP-sensitive K channel opener), flecainide (an antiarrhythmic drug), and sodium nitroprusside (SNP) (an NO donor). Sildenafil (a phosphodiesterase-5 inhibitor) further increased the pinacidil-induced augmentation of I. In paper, here I review the NCX stimulants that enhance NCX function among the cardioprotective agents we examined such as nicorandil, pinacidil, SNP, sildenafil and flecainide, in addition to atrial natriuretic (ANP) and dofetilide, which were reported by other investigators.
- | Review, Journal: Anti-Arrhythmic Drug Therapy in Implantable Cardioverter-Defibrillator Recipients. (Pubmed Central) - Mar 4, 2020
Dofetilide, azimilide and ranolazine are emerging as therapeutic options for secondary prevention; more studies are needed to assess efficacy and safety in comparison to currently used agents. Beta blockers and amiodarone are the mainstay of therapy in patients experiencing electrical storm; their use reduces the frequency of ventricular arrhythmias and ICD intervention as well as affording time until catheter ablation can be considered.
- | Stedicor (azimilide dihydrochloride) / AbbVie
Journal: Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant. (Pubmed Central) - Aug 17, 2019
Beta blockers and amiodarone are the mainstay of therapy in patients experiencing electrical storm; their use reduces the frequency of ventricular arrhythmias and ICD intervention as well as affording time until catheter ablation can be considered. The results suggest that the KCNH2 VUS may be classified as potentially pathogenic.
- | Stedicor (azimilide dihydrochloride) / AbbVie
Journal: Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial. (Pubmed Central) - Jun 2, 2017
The SHIELD-2 trial was statistically underpowered due to early trial termination and did not meet its primary objective. Despite this limitation, azimilide showed promise as a safe and effective drug in reducing all-cause shocks, unplanned hospitalizations, and ED visits in ICD patients.
- | Stedicor (azimilide dihydrochloride) / AbbVie
Trial termination: Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2) (clinicaltrials.gov) - May 1, 2013
P3, N=240, Terminated, Sponsor: Forest Laboratories
Despite this limitation, azimilide showed promise as a safe and effective drug in reducing all-cause shocks, unplanned hospitalizations, and ED visits in ICD patients. Recruiting --> Terminated
- | Stedicor (azimilide dihydrochloride) / AbbVie
Enrollment change: Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2) (clinicaltrials.gov) - May 1, 2013
P3, N=240, Terminated, Sponsor: Forest Laboratories
Recruiting --> Terminated N=890 --> 240
- || Stedicor (azimilide dihydrochloride) / AbbVie
New P3 trial: Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2) (clinicaltrials.gov) - Nov 1, 2011
P3, N=240, Terminated, Sponsor: Forest Laboratories